Caption Management, LLC Aldeyra Therapeutics, Inc. Call Options Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$2.43 - $4.85 $461,700 - $921,499	-190,000 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.25 - $5.17 $1.46 Million - $2.32 Million	-449,700 Reduced 70.3%	190,000 $846,000
Q4 2021 Feb 11, 2022	SELL	$3.5 - $9.63 $297,850 - $819,513	-85,100 Reduced 11.74%	639,700 $2.56 Million
Q3 2021 Nov 12, 2021	BUY	$7.94 - $11.31 $4.8 Million - $6.84 Million	604,800 Added 504.0%	724,800 $6.36 Million
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $1.06 Million - $1.51 Million	101,500 Added 548.65%	120,000 $1.36 Million
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $120,805 - $266,770	18,500 New	18,500 $219,000
Q2 2019 Aug 13, 2019	SELL	$6.0 - $9.0 $324,000 - $486,000	-54,000 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$7.14 - $9.85 $385,560 - $531,900	54,000 New	54,000 $487,000
Q4 2018 Jan 30, 2019	SELL	$7.26 - $13.29 $181,500 - $332,250	-25,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $170,000 - $358,750	25,000 New	25,000 $345,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $285M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.